DelveInsight’s, “Extensive-Stage Small Cell Lung Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer pipeline landscape. It covers the Extensive-Stage Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Extensive-Stage Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Extensive-Stage Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key Extensive-Stage Small Cell Lung Cancer Companies, and future Extensive-Stage Small Cell Lung Cancer treatment landscapes @ Extensive-Stage Small Cell Lung Cancer Pipeline Outlook Report
Key Takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Report
- In February 2025:- AIO-Studien-gGmbH:- Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver and brain. Compared with non-small-cell lung cancer (NSCLC) SCLC has a unique natural history with a shorter doubling time, higher growth fraction, earlier development of widespread metastases, and uniform initial response to chemo- or radiotherapy.
- In February 2025:- Merck Sharpy & Dohme LLC:- This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival.
- In February 2025:- Amgen:- A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab.
- In February 2025:- AstraZeneca:- Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer. In this single arm study participants will be treated with with durvalumab alone and concurrently with platinum-based chemotherapy and etoposide during the study period until radiological disease progression, unless there is clinical progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met, as per investigator assessment.
- In February 2025:- Georgetown University:- Participants enrolled in the trial will receive MGC018 through an intravenous (IV) infusion, every 28 days until disease progression or unacceptable toxicity. Tumor assessment will be done every 2 cycles (28 day cycles). Blood samples will be taken for biomarker analysis before treatment, on cycle 3 day 1, and at progression. A pretreatment biopsies will be done.
- DelveInsight’s Extensive-Stage Small Cell Lung Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Extensive-Stage Small Cell Lung Cancer treatment.
- The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, and Merck Sharp & Dohme LLC and others.
- Promising Extensive-Stage Small Cell Lung Cancer pipeline therapies such as Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others.
Discover how the Extensive-Stage Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Extensive-Stage Small Cell Lung Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Extensive-Stage Small Cell Lung Cancer Clinical Trials and Studies
Extensive-Stage Small Cell Lung Cancer Emerging Drugs
- Serplulimab+Chemo: Shanghai Henlius Biotech
Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
- Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
- RYZ101: RayzeBio, Inc.
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC).
The Extensive-Stage Small Cell Lung Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Extensive-Stage Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Extensive-Stage Small Cell Lung Cancer Treatment.
- Extensive-Stage Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Extensive-Stage Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Extensive-Stage Small Cell Lung Cancer market.
Get a detailed analysis of the latest innovations in the Extensive-Stage Small Cell Lung Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Extensive-Stage Small Cell Lung Cancer Unmet Needs
Extensive-Stage Small Cell Lung Cancer Companies
Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, and Merck Sharp & Dohme LLC and others.
Extensive-Stage Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Extensive-Stage Small Cell Lung Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Extensive-Stage Small Cell Lung Cancer Therapies and key Extensive-Stage Small Cell Lung Cancer Developments @ Extensive-Stage Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Extensive-Stage Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- Extensive-Stage Small Cell Lung Cancer Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, and Merck Sharp & Dohme LLC and others.
- Extensive-Stage Small Cell Lung Cancer pipeline therapies- Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others.
- Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Extensive-Stage Small Cell Lung Cancer drug development? Find out in DelveInsight’s exclusive Extensive-Stage Small Cell Lung Cancer Pipeline Report—access it now! @ Extensive-Stage Small Cell Lung Cancer Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Serplulimab+Chemo: Shanghai Henlius Biotech
- Drug profiles in the detailed report…..
- Mid-Stage Products (Phase II)
- Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RYZ101: RayzeBio, Inc.
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
- Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
- Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
- Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
- Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
- Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
- Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/lymphoedema-market
